Endoscopy Devices for Obesity, Type II Diabetes and NASH Market by Product (Endoscope, Mechanical Endoscopic Equipment, Visualization and Documentation Systems, Accessories, and Other Endoscopy Equipment), Procedure (Gastric Balloon, Aspiration Therapy, Endoscopic Sleeve Gastroplasty, Gastric Injection, and Lap Band Surgery), and Disease Indication (Obesity, Type II Diabetes, and Nonalcoholic Steatohepatitis [NASH]): Global Opportunity Analysis and Industry Forecast, 2021–2028

ALL4621742
266 Pages
June 2021
Medical Devices

Download Sample Get Discount

The global endoscopy devices for obesity, type II diabetes and NASH market was valued at $2,638.99 million in 2019, and is projected to reach $3,711.43 million by 2027, registering a CAGR of 7.6% from 2021 to 2028. Endoscopy devices are the medical devices with light attached to look inside the body cavity or organ by inserting through a natural opening such as the mouth or through incisions. An endoscopy is the minimally invasive medical procedure that diagnoses, prevents, and treats complications associated with visceral organs. Endoscopic devices consist of flexible tubing that contains a series of lighted mirror lenses and optic fibers. These devices are used in the diagnosis of gastrointestinal tract, small intestine, large intestine/colon, bile duct, rectum, respiratory tract, ear, urinary tract, and female reproductive systems. The market mainly focuses on the endoscopic devices used in the endoscopic surgeries used in treating diseases such as obesity, type II diabetes, and non-alcoholic steatohepatitis.

Surge in obese population, technological advancements, rise in prevalence rate of diseases that require endoscopy devices, growth in patient preference for minimally invasive surgeries, favorable FDA approvals, and reimbursement policies in developed economies, shorter recovery time and minimal postoperative complications are the key factors that fuel the growth of the endoscopy devices for obesity, type II diabetes and NASH market. Furthermore, rise in prevalence of diabetes within the population is expected to supplement the market growth throughout the analysis period. For instance, according to the data published by National Institute of Health (NIH), in 2017, approximately 462 million individuals were affected by type II diabetes, corresponding to 6.28% of the world’s population. Moreover, increase in the geriatric population vulnerable to obesity and comorbid conditions related to obesity, which necessitates the use of endoscopic procedures for diagnosis & treatment is anticipated to boost the market growth in near future. However, dearth of trained physicians & endoscopists and infections associated with the use of endoscopes are expected to hinder the growth of the market.

The global endoscopy devices for obesity, type II diabetes and NASH market is segmented into product type, procedure, disease indication, and region. By product type, the market is categorized into endoscope, mechanical endoscopic equipment, visualization & documentation systems, accessories, and other endoscopy equipment. By procedure, the market is segmented into gastric balloon, aspiration therapy, endoscopic sleeve gastroplasty, gastric injection, and lap band surgery. On the basis of disease indication, the endoscopy devices for obesity, type II diabetes and NASH market is classified into obesity, type II diabetes and nonalcoholic steatohepatitis (NASH). Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

 This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2028, which assists to identify the prevailing market opportunities.

 An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.

 A comprehensive analysis of the factors that drive and restrain the growth of the global endoscopy devices for obesity, type II diabetes and NASH market is provided.

 An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

KEY MARKET SEGMENTS

• By Product

o Endoscope

o Mechanical endoscopic equipment

o Visualization and documentation systems

o Accessories

o Other endoscopy equipment

• By Procedure

o Gastric balloon

o Aspiration therapy

o Endoscopic sleeve gastroplasty

o Gastric injection

o Lap band surgery

• By Disease indication

o Obesity

o Type II Diabetes

o Nonalcoholic Steatohepatitis (NASH

• By Region

o North America

 U.S.

 Canada

 Mexico

o Europe

 Germany

 France

 UK

 Rest of Europe

o Asia-Pacific

 Japan

 China

 India

 Australia

 Rest of Asia-Pacific

o LAMEA

 Brazil

 Saudi Arabia

 South Africa

 Rest of LAMEA

KEY MARKET PLAYERS

• Apollo Endosurgery Inc.

• Aspire Bariatrics Inc.

• Endo Tools Therapeutics S.A

• Fractyl Laboratories Inc.

• GI Dynamics Inc.

• GI Windows Inc.

• Medtronic plc

• Obalon Therapeutics Inc.

• ReShape Lifesciences Inc.

• Spatz FGIA Inc.

• USGI Medical Inc.

CHAPTER 1:INTRODUCTION

1.1.Report description

1.2.Key benefits for stakeholders

1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study

2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.2.2.Top winning strategies

3.3.Porter’s five force analysis

3.4.Top player positioning, 2019

3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Surge in obese population

3.5.1.2.Technological advancements

3.5.1.3.Rise in prevalence rate of diseases that require endoscopy devices

3.5.1.4.Growth in patient preference for minimally invasive surgeries

3.5.1.5.Favorable FDA approvals

3.5.1.6.Shorter recovery time and minimal postoperative complications

3.5.2.Restraints

3.5.2.1.Dearth of trained physicians and endoscopists

3.5.2.2.Infections caused by few endoscopes

3.5.3.Opportunities

3.5.3.1.Unmet medical demands in developing countries

3.5.3.2.Lucrative opportunities in emerging economies

3.6.COVID-19 impact analysis

3.7.Clinical data analysis

3.7.1.Intragastric balloons

3.7.2.AspireAssist

3.7.3.Revita DMR System

3.7.4.EndoBarrier

3.7.5.Incision-less Anastomosis System (IAS)

3.7.6.OverStitch Endoscopic Suturing System

3.7.7.Endomina

3.7.8.Plication Device

3.7.9.Endostitch

CHAPTER 4:ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT

4.1.Overview

4.1.1.Market size and forecast

4.2.Endoscopes

4.2.1.Key market trends, growth factors, and opportunities

4.2.2.Market size and forecast, by region

4.2.3.Market analysis, by country

4.3.Mechanical endoscopic equipment

4.3.1.Key market trends, growth factors, and opportunities

4.3.2.Market size and forecast

4.3.3.Market analysis, by country

4.4.Visualization and documentation systems

4.4.1.Key market trends, growth factors, and opportunities

4.4.2.Market size and forecast

4.4.3.Market analysis, by country

4.5.Accessories

4.5.1.Key market trends, growth factors, and opportunities

4.5.2.Market size and forecast

4.5.3.Market analysis, by country

4.6.Other endoscopy equipment

4.6.1.Key market trends, growth factors, and opportunities

4.6.2.Market size and forecast

4.6.3.Market analysis, by country

CHAPTER 5:ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE

5.1.Overview

5.1.1.Market size and forecast

5.2.Gastric balloons

5.2.1.Key market trends and opportunities

5.2.2.Market size and forecast

5.2.3.Market analysis, by country

5.3.Aspiration therapy

5.3.1.Key trends and opportunities

5.3.2.Market size and forecast

5.3.3.Market analysis, by country

5.4.Endoscopic sleeve gastroplasty

5.4.1.Key market trends and opportunities

5.4.2.Market size and forecast

5.4.3.Market analysis, by country

5.5.Gastric injections

5.5.1.Key market trends and opportunities

5.5.2.Market size and forecast

5.5.3.Market analysis, by country

5.6.Lap band surgery

5.6.1.Key market trends and opportunities

5.6.2.Market size and forecast

5.6.3.Market analysis, by country

5.7.Others

5.7.1.Key market trends and opportunities

5.7.2.Market size and forecast

5.7.3.Market analysis, by country

CHAPTER 6:ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION

6.1.Overview

6.1.1.Market size and forecast

6.2.Obesity

6.2.1.Key market trends, growth factors and opportunities

6.2.2.Market size and forecast, by region

6.2.3.Market share analysis, by country

6.3.Type II Diabetes

6.3.1.Key market trends, growth factors and opportunities

6.3.2.Market size and forecast, by region

6.3.3.Market share analysis, by country

6.4.Nonalcoholic Steatohepatitis (NASH)

6.4.1.Key market trends, growth factors and opportunities

6.4.2.Market size and forecast, by region

6.4.3.Market share analysis, by country

CHAPTER 7:ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities

7.2.2.Market size and forecast, by country

7.2.3.Market size and forecast, by product type

7.2.4.Market size and forecast, by procedure

7.2.5.Market size and forecast, by disease indication

7.2.5.1.U.S.

7.2.5.1.1.U.S. Endoscopy devices for obesity, type II diabetes and NASH market, by product type

7.2.5.1.2.U.S. Endoscopy devices for obesity, type II diabetes and NASH market, by procedure

7.2.5.1.3.U.S. Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication

7.2.5.2.Canada

7.2.5.2.1.Canada Endoscopy devices for obesity, type II diabetes and NASH market, by product type

7.2.5.2.2.Canada Endoscopy devices for obesity, type II diabetes and NASH market, by procedure

7.2.5.2.3.Canada Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication

7.2.5.3.Mexico

7.2.5.3.1.Mexico Endoscopy devices for obesity, type II diabetes and NASH market, by product type

7.2.5.3.2.Mexico Endoscopy devices for obesity, type II diabetes and NASH market, by procedure

7.2.5.3.3.Mexico Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities

7.3.2.Market size and forecast, by country

7.3.2.1.Germany

7.3.2.1.1.Germany Endoscopy devices for obesity, type II diabetes and NASH market, by product type

7.3.2.1.2.Germany Endoscopy devices for obesity, type II diabetes and NASH market, by procedure

7.3.2.1.3.Germany Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication

7.3.2.2.France

7.3.2.2.1.France Endoscopy devices for obesity, type II diabetes and NASH market, by product type

7.3.2.2.2.France Endoscopy devices for obesity, type II diabetes and NASH market, by procedure

7.3.2.2.3.France Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication

7.3.2.3.U.K.

7.3.2.3.1.U.K. Endoscopy devices for obesity, type II diabetes and NASH market, by product type

7.3.2.3.2.U.K. Endoscopy devices for obesity, type II diabetes and NASH market, by procedure

7.3.2.3.3.U.K. Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication

7.3.2.4.Italy

7.3.2.4.1.Italy Endoscopy devices for obesity, type II diabetes and NASH market, by product type

7.3.2.4.2.Italy Endoscopy devices for obesity, type II diabetes and NASH market, by procedure

7.3.2.4.3.Italy Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication

7.3.2.5.Spain

7.3.2.5.1.Spain Endoscopy devices for obesity, type II diabetes and NASH market, by product type

7.3.2.5.2.Spain Endoscopy devices for obesity, type II diabetes and NASH market, by procedure

7.3.2.5.3.Spain Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication

7.3.2.6.Rest of Europe

7.3.2.6.1.Rest of Europe Endoscopy devices for obesity, type II diabetes and NASH market, by product type

7.3.2.6.2.Rest of Europe Endoscopy devices for obesity, type II diabetes and NASH market, by procedure

7.3.2.6.3.Rest of Europe Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities

7.4.2.Market size and forecast, by country

7.4.3.Market size and forecast, by product type

7.4.4.Market size and forecast, by procedure

7.4.5.Market size and forecast, by disease indication

7.4.5.1.China

7.4.5.1.1.China Endoscopy devices for obesity, type II diabetes and NASH market, by product type

7.4.5.1.2.China endoscopy devices for obesity, type II diabetes and NASH market, by procedure

7.4.5.1.3.China endoscopy devices for obesity, type II diabetes and NASH market, by disease indication

7.4.5.2.Japan

7.4.5.2.1.Japan Endoscopy devices for obesity, type II diabetes and NASH market, by product type

7.4.5.2.2.Japan endoscopy devices for obesity, type II diabetes and NASH market, by procedure

7.4.5.2.3.Japan endoscopy devices for obesity, type II diabetes and NASH market, by disease indication

7.4.5.3.India

7.4.5.3.1.India Endoscopy devices for obesity, type II diabetes and NASH market, by product type

7.4.5.3.2.India endoscopy devices for obesity, type II diabetes and NASH market, by procedure

7.4.5.3.3.India endoscopy devices for obesity, type II diabetes and NASH market, by disease indication

7.4.5.4.Australia

7.4.5.4.1.Australia Endoscopy devices for obesity, type II diabetes and NASH market, by product type

7.4.5.4.2.Australia Endoscopy devices for obesity, type II diabetes and NASH market, by procedure

7.4.5.4.3.Australia Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication

7.4.5.5.Rest of Asia-Pacific

7.4.5.5.1.Rest of Asia-Pacific Endoscopy devices for obesity, type II diabetes and NASH market, by product type

7.4.5.5.2.Rest of Asia-Pacific Endoscopy devices for obesity, type II diabetes and NASH market, by procedure

7.4.5.5.3.Rest of Asia-Pacific Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities

7.5.2.Market size and forecast, by country

7.5.3.Market size and forecast, by product type

7.5.4.Market size and forecast, by procedure

7.5.5.Market size and forecast, by disease indication

7.5.5.1.Brazil

7.5.5.1.1.Brazil Endoscopy devices for obesity, type II diabetes and NASH market, by product type

7.5.5.1.2.Brazil Endoscopy devices for obesity, type II diabetes and NASH market, by procedure

7.5.5.1.3.Brazil Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication

7.5.5.2.Saudi Arabia

7.5.5.2.1.Saudi Arabia Endoscopy devices for obesity, type II diabetes and NASH market, by product type

7.5.5.2.2.Saudi Arabia Endoscopy devices for obesity, type II diabetes and NASH market, by procedure

7.5.5.2.3.Saudi Arabia Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication

7.5.5.3.South Africa

7.5.5.3.1.South Africa Endoscopy devices for obesity, type II diabetes and NASH market, by product type

7.5.5.3.2.South Africa Endoscopy devices for obesity, type II diabetes and NASH market, by procedure

7.5.5.3.3.South Africa Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication

7.5.5.4.Rest of LAMEA

7.5.5.4.1.Rest of LAMEA Endoscopy devices for obesity, type II diabetes and NASH market, by product type

7.5.5.4.2.Rest of LAMEA Endoscopy devices for obesity, type II diabetes and NASH market, by procedure

7.5.5.4.3.Rest of LAMEA Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication

CHAPTER 8:COMPANY PROFILES

8.1.APOLLO ENDOSURGERY INC.

8.1.1.Company overview

8.1.2.Company snapshot

8.1.3.Operating business segments

8.1.4.Product portfolio

8.1.5.Business performance

8.2.ASPIRE BARIATRICS INC.

8.2.1.Company overview

8.2.2.Company snapshot

8.2.3.Operating business segment

8.2.4.Product portfolio

8.2.5.Key strategic moves and developments

8.3.ENDO TOOLS THERAPEUTICS S.A.

8.3.1.Company overview

8.3.2.Company snapshot

8.3.3.Operating business segment

8.3.4.Product portfolio

8.4.FRACTYL LABORATORIES INC.

8.4.1.Company overview

8.4.2.Company snapshot

8.4.3.Operating business segment

8.4.4.Product portfolio

8.4.5.Key strategic moves and developments

8.5.GI DYNAMICS INC.

8.5.1.Company overview

8.5.2.Company snapshot

8.5.3.Operating business segment

8.5.4.Product portfolio

8.5.5.Key strategic moves and developments

8.6.GI WINDOWS INC.

8.6.1.Company overview

8.6.2.Company snapshot

8.6.3.Operating business segment

8.6.4.Product portfolio

8.6.5.Key strategic moves and developments

8.7.MEDTRONIC PLC.

8.7.1.Company overview

8.7.2.Company snapshot

8.7.3.Operating business segments

8.7.4.Product portfolio

8.7.5.Business performance

8.8.OBALON THERAPEUTICS INC.

8.8.1.Company overview

8.8.2.Company snapshot

8.8.3.Operating business segment

8.8.4.Product portfolio

8.8.5.Business Performance

8.9.RESHAPE LIFESCIENCES INC.

8.9.1.Company overview

8.9.2.Company snapshot

8.9.3.Product portfolio

8.9.4.Business performance

8.9.5.Key strategic moves and developments

8.10.SPATZ FGIA INC.

8.10.1.Company overview

8.10.2.Company snapshot

8.10.3.Operating business segment

8.10.4.Product portfolio

8.11.USGI MEDICAL INC.

8.11.1.Company overview

8.11.2.Company snapshot

8.11.3.Operating business segments

8.11.4.Product portfolio

8.11.5.Key strategic moves and developments

LIST OF TABLES

TABLE 01.OVERVIEW OF FDA STATUS FOR DEVICES USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES

TABLE 02.CLINICAL DATA OF THE GASTRIC BALLOONS USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES

TABLE 03.CLINICAL DATA OF THE OTHER GASTRIC BALLOONS USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES

TABLE 04.CLINICAL PIPELINE ANALYSIS OF GASTRIC BALLOONS

TABLE 05.CLINICAL DATA OF THE ASPIRATION THERAPY DEVICE USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES

TABLE 06.CLINICAL PIPELINE ANALYSIS OF ASPIRATION THERAPY DEVICE

TABLE 07.CLINICAL DATA OF THE REVITA DMR SYSTEM USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES

TABLE 08.CLINICAL PIPELINE ANALYSIS OF REVITA DMR SYSTEM

TABLE 09.CLINICAL DATA OF ENDOBARRIER USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES

TABLE 10.CLINICAL PIPELINE ANALYSIS OF ENDOBARRIER

TABLE 11.CLINICAL DATA OF INCISION-LESS ANASTOMOSIS SYSTEM (IAS) USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES

TABLE 12.CLINICAL PIPELINE ANALYSIS OF INCISIONLESS ANASTOMOSIS

TABLE 13.CLINICAL DATA OF OVERSTITCH USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES

TABLE 14.CLINICAL PIPELINE ANALYSIS OF OVERSTITCH ENDOSCOPIC SUTURING SYSTEM

TABLE 15.CLINICAL DATA OF ENDOMINA USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES

TABLE 16.CLINICAL PIPELINE ANALYSIS OF ENDOMINA

TABLE 17.CLINICAL DATA OF PLICATION DEVICE USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES

TABLE 18.CLINICAL PIPELINE ANALYSIS OF PLICATION DEVICE

TABLE 19.CLINICAL DATA OF ENDOSTITCH USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES

TABLE 20.CLINICAL PIPELINE ANALYSIS OF ENDOSTITCH

TABLE 21.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019–2028 ($MILLION)

TABLE 22.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR ENDOSCOPES BY REGION, 2019–2028 ($MILLION)

TABLE 23.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR MECHANICAL ENDOSCOPIC EQUIPMENT, BY REGION, 2019–2028 ($MILLION)

TABLE 24.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR VISUALIZATION AND DOCUMENTATION SYSTEM, BY REGION, 2019–2028 ($MILLION)

TABLE 25.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR ACCESSORIES, BY REGION, 2019–2028 ($MILLION)

TABLE 26.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR OTHER ENDOSCOPY EQUIPMENT, BY REGION, 2019–2028 ($MILLION)

TABLE 27.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019–2028 ($MILLION)

TABLE 28.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR GASTRIC BALLOONS, BY REGION, 2019–2028 ($MILLION)

TABLE 29.ENDOSOCOPY DEVICES MARKET FOR ASPIRATION THEREAPY, BY REGION, 2019–2028 ($MILLION)

TABLE 30.ENDOSCOPIC DEVICES MARKET FOE ENDOSCOPIC SLEEVE GASTROPLASTY, BY REGION, 2019–2028 ($MILLION)

TABLE 31.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR GASTRIC INJECTION, BY REGION, 2019–2028 ($MILLION)

TABLE 32.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET LAP BAND SURGERY, BY REGION, 2019–2028 ($MILLION)

TABLE 33.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET OTHERS, BY REGION, 2019–2028 ($MILLION)

TABLE 34.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION 2019-2028($MILLION)

TABLE 35.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR OBESITY, BY REGION, 2019-2028 ($MILLION)

TABLE 36.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR TYPE II DIABETES, BY REGION, 2019-2028 ($MILLION)

TABLE 37.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR NONALCOHOLIC STEATOHEPATITIS (NASH), BY REGION, 2019-2028 ($MILLION)

TABLE 38.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY REGION, 2019-2028 ($MILLION)

TABLE 39.NORTH AMERICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY COUNTRY, 2019-2028 ($MILLION)

TABLE 40.NORTH AMERICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT TYPE, 2019-2028 ($MILLION)

TABLE 41.NORTH AMERICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028 ($MILLION)

TABLE 42.NORTH AMERICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028 ($MILLION)

TABLE 43.U.S. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT TYPE, 2019-2028

TABLE 44.U.S. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028

TABLE 45.U.S. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028

TABLE 46.CANADA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028

TABLE 47.CANADA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028

TABLE 48.CANADA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028

TABLE 49.MEXICO ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028

TABLE 50.MEXICO ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028

TABLE 51.MEXICO ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028

TABLE 52.EUROPE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY COUNTRY, 2019-2028 ($MILLION)

TABLE 53.GERMANY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028

TABLE 54.GERMANY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028

TABLE 55.GERMANY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028

TABLE 56.FRANCE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028

TABLE 57.FRANCE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028

TABLE 58.FRANCE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028

TABLE 59.U.K. ENDOSCOPY DEVICES MARKET FOR OBESITY, TYPE II DIABETES, AN BGT5D NASH, BY PRODUCT, 2019-2028

TABLE 60.U.K. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028

TABLE 61.U.K. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028

TABLE 62.ITALY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028

TABLE 63.ITALY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028

TABLE 64.ITALY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028

TABLE 65.SPAIN ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028

TABLE 66.SPAIN ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028

TABLE 67.ITALY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028

TABLE 68.REST OF EUROPE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028

TABLE 69.REST OF EUROPE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028

TABLE 70.REST OF EUROPE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028

TABLE 71.ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY COUNTRY, 2019-2028 ($MILLION)

TABLE 72.ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT TYPE, 2019-2028 ($MILLION)

TABLE 73.ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028 ($MILLION)

TABLE 74.ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028 ($MILLION)

TABLE 75.CHINA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028

TABLE 76.CHINA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028

TABLE 77.CHINA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028

TABLE 78.JAPAN ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028

TABLE 79.JAPAN ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028

TABLE 80.JAPAN ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028

TABLE 81.INDIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028

TABLE 82.INDIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028

TABLE 83.INDIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028

TABLE 84.AUSTRALIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028

TABLE 85.AUSTRALIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028

TABLE 86.AUSTRALIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028

TABLE 87.REST OF ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028

TABLE 88.REST OF ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028

TABLE 89.REST OF ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028

TABLE 90.LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY COUNTRY, 2019-2028 ($MILLION)

TABLE 91.LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT TYPE, 2019-2028 ($MILLION)

TABLE 92.LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028 ($MILLION)

TABLE 93.LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028 ($MILLION)

TABLE 94.BRAZIL ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028

TABLE 95.BRAZIL ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028

TABLE 96.BRAZIL ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028

TABLE 97.SAUDI ARABIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028

TABLE 98.SAUDI ARABIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028

TABLE 99.SAUDI ARABIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028

TABLE 100.SOUTH AFRICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028

TABLE 101.SOUTH AFRICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028

TABLE 102.SOUTH AFRICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028

TABLE 103.REST OF LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028

TABLE 104.REST OF LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028

TABLE 105.REST OF LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028

TABLE 106.APOLLO ENDOSURGERY: COMPANY SNAPSHOT

TABLE 107.APOLLO ENDOSURGERY: OPERATING SEGMENT

TABLE 108.APOLLO ENDOSURGERY: PRODUCT PORTFOLIO

TABLE 109.ASPIRE BARIATRICS: COMPANY SNAPSHOT

TABLE 110.ASPIRE BARIATRICS: OPERATING SEGMENT

TABLE 111.ASPIRE BARIATRICS: PRODUCT PORTFOLIO

TABLE 112.ASPIRE BARIATRICS: PRODUCT PORTFOLIO

TABLE 113.ENDO TOOLS THERAPEUTICS: COMPANY SNAPSHOT

TABLE 114.ENDO TOOLS THERAPEUTICS: OPERATING SEGMENT

TABLE 115.ENDO TOOLS THERAPEUTICS: PRODUCT PORTFOLIO

TABLE 116.FRACTYL LABORATORIES: COMPANY SNAPSHOT

TABLE 117.FRACTYL LABORATORIES: OPERATING SEGMENTS

TABLE 118.FRACTYL LABORATORIES: PRODUCT PORTFOLIO

TABLE 119.FRACTYL LABORATORIES: PRODUCT PORTFOLIO

TABLE 120.GI DYNAMICS: COMPANY SNAPSHOT

TABLE 121.GI DYNAMICS: OPERATING SEGMENT

TABLE 122.GI DYNAMICS: PRODUCT PORTFOLIO

TABLE 123.GI DYNAMICS: PRODUCT PORTFOLIO

TABLE 124.GI WINDOWS: COMPANY SNAPSHOT

TABLE 125.GI WINDOWS: OPERATING SEGMENT

TABLE 126.GI WINDOWS: PRODUCT PORTFOLIO

TABLE 127.GI WINDOWS: PRODUCT PORTFOLIO

TABLE 128.MEDTRONIC: COMPANY SNAPSHOT

TABLE 129.MEDTRONIC: OPERATING BUSINESS SEGMENTS

TABLE 130.MEDTRONIC: PRODUCT PORTFOLIO

TABLE 131.OBALON THERAPEUTICS INC.: COMPANY SNAPSHOT

TABLE 132.OBALON THERAPEUTICS: OPERATING SEGMENT

TABLE 133.OBALON THERAPEUTICS: PRODUCT PORTFOLIO

TABLE 134.RESHAPE LIFESCIENCES: COMPANY SNAPSHOT

TABLE 135.RESHAPE LIFESCIENCES INC.: PRODUCT PORTFOLIO

TABLE 136.RESHAPE LIFESCIENCES: PRODUCT PORTFOLIO

TABLE 137.SPATZ FGIA: COMPANY SNAPSHOT

TABLE 138.SPATZ FGIA: OPERATING SEGMENT

TABLE 139.SPATZ FGIA: PRODUCT PORTFOLIO

TABLE 140.USGI MEDICAL: COMPANY SNAPSHOT

TABLE 141.USGI MEDICAL: OPERATING SEGMENTS

TABLE 142.USGI MEDICAL: PRODUCT PORTFOLIO

TABLE 143.RESHAPE LIFESCIENCES: PRODUCT PORTFOLIO

Purchase Options

Data Pack $4125 Single User License $6168 Five User $6929 Enterprise User License $9663

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Need More Information

Contact Us

+ 1-888-961-4454

Drop Us an email at

help@bigmarketresearch.com

Medical implants are permanent devices such as pacemakers or temporary devices such as fracture plates which are removed once their function is completed. These implants are made up of bone, tissue, skin, ceramics, metals, plastics, and other natural materials...

Publish Date: August 21, 2016
$5370

View Details

Ostomy Drainage Bags Market by Type (Colostomy Bags, Ileostomy Bags, Urostomy Bags, Continent Urostomy Bags, and Continent Ileostomy Bags) - Global Opportunity Analysis and Industry Forecast, 2014-2022

Ostomy is a surgery wherein an artificial opening, known as stoma, is created from the colon in the human body to eliminate body wastes such as urine, mucus, and stools, which are collected in artificial bags called ostomy drainage bags. These plastic/rub...

Publish Date: December 1, 2016
$5370

View Details

Laparoscopy Devices Market by Product (Laparoscopes, Energy Devices, Insufflators, Robot-Assisted Surgery Systems, Suction or Irrigation Systems, Closure Devices, Hand Instruments, Access Devices, Accessories, and Other Laparoscopy Devices), Application {General Surgery (Cholecystectomies, Hernia Repairs, Appendectomies, Anti-reflux Surgeries, and Others), Bariatric Surgery (Gastric Bypass, Sleeve gastrectomy, Gastric Banding, and Others), Gynecological Surgery, Urological Surgery, Colorectal Surgery, and Others}, and End User (Hospitals, Clinics, and Other End Users) - Global Opportunity Analysis and Industry Forecast, 2014-2022

Laparoscopy is a minimally invasive procedure used to examine organs inside the abdomen or pelvic cavities by inserting a laparoscope through a small incision in the abdomen. A laparoscope comprises a long, thin tube with high-intensity light, and high-re...

Publish Date: April 24, 2017
$5370

View Details

Client Testimonials

Your team has worked hard to help and to provide our research needs to fulfill our significant initiatives...

Maria

-Researcher

The report on EAA resins was detailed and informative. However, we were hopeful to discover a Chinese producer ...

David

-President Protech Oxyplast Group

Thanks the attached report is perfect and accurate, but I was wondering if you can show the price trend in one year...

Contact Us

Drop Us an email at

Similar Reports

Client Testimonials

Maria

David

Sara